Canopy Growth (CGC) Cash from Financing Activities (2019 - 2026)
Canopy Growth (CGC) posted Cash from Financing Activities of $204.9 million for Q4 2025, up 1015.35% sequentially from $18.4 million in Q2 2025, and up 1051.17% YoY from $17.8 million in Q4 2024.
Canopy Growth (CGC) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Canopy Growth has reported Cash from Financing Activities for 7 years, with the latest figure at $204.9 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 1051.17% year-over-year to $204.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $267.0 million (up 109.76% YoY) and the FY2026 annual result came in at $242.4 million, up 133.96% from the prior year.
- Cash from Financing Activities rose to $204.9 million in Q4 2025 per CGC's latest filing, from $18.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $786.6 million in Q1 2021 and troughed at -$204.5 million in Q3 2023.
- A 5-year average of $40.7 million and a median of -$273368.7 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 36245.01% in 2022, then jumped 14591.67% in 2023.
- Over 5 years, Cash from Financing Activities stood at $272114.3 in 2021, then tumbled by 36245.01% to -$98.4 million in 2022, then jumped by 50.54% to -$48.6 million in 2023, then surged by 55.71% to -$21.5 million in 2024, then surged by 1051.17% to $204.9 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $204.9 million, $18.4 million, and -$21.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Canopy Growth | 449.71 Mn | 202.70 Mn | 16.08 Mn | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.40 Mn |
| Jun 30, 2026 | -5.40 Mn |
| Dec 31, 2025 | 204.94 Mn |
| Dec 31, 2025 | 204.94 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Dec 31, 2024 | -21.55 Mn |
| Dec 31, 2024 | -21.55 Mn |
| Sep 30, 2024 | 65.20 Mn |
| Sep 30, 2024 | 65.20 Mn |
| Jun 30, 2024 | 77.34 Mn |
| Jun 30, 2024 | 77.34 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Dec 31, 2023 | -48.65 Mn |
| Dec 31, 2023 | -48.65 Mn |
| Sep 30, 2023 | -204.53 Mn |
| Sep 30, 2023 | -204.53 Mn |
| Jun 30, 2023 | -99.09 Mn |
| Jun 30, 2023 | -99.09 Mn |